Company news
Vaxcyte, Inc. (NASDAQ:PCVX) news
Every Vaxcyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
October 4, 2026
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
September 3, 2026
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
July 8, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
June 2, 2026
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
March 22, 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 17, 2026
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 24, 2026
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 11, 2026
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
February 10, 2026
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 5, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 2, 2026
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 29, 2026
Vaxcyte Announces Pricing of $550 Million Public Offering
January 28, 2026
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 21, 2026
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
December 7, 2025
Medicxi Announces €500 Million Fund V
November 14, 2025
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
November 3, 2025
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
September 29, 2025
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
September 2, 2025
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
August 5, 2025
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
April 30, 2025
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
March 30, 2025
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
March 29, 2025
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 24, 2025
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
February 11, 2025
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
February 4, 2025
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
January 29, 2025
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
December 2, 2024
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
November 11, 2024
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
November 4, 2024
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 5, 2024
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
September 3, 2024
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 2, 2024
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 1, 2024
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 5, 2024
Vaxcyte Appoints John Furey to Board of Directors
July 1, 2024
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 1, 2024
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
March 3, 2024
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 26, 2024
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 14, 2024
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 1, 2024
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
January 31, 2024
Vaxcyte Announces Pricing of $750 Million Public Offering
January 29, 2024
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
January 28, 2024